3 ms·

Pfizer has the highest efficacy endpoint (95% at preventing symptomatic infection, which would theoretically also prevent spread and symptoms at higher percenta

Pfizer has the highest efficacy endpoint (95% at preventing symptomatic infection, which would theoretically also prevent spread and symptoms at higher percentages) with equal efficacy across age groups. Moderna is 95% at preventing symptoms (100% for serious symptoms in their trial but insufficient sample size). They also reported slightly lower efficacy for the elderly. AstraZeneca is 62% for preventing symptoms (unknown for infection and spread). So it's not quite a trade-off of spread prevention vs symptom prevention, because Pfizer claims to do both significantly better. edit: reading the data in more detail, all 3 don't have sufficiently significant data to claim anything other than symptoms. So preventing spread is just PR-hype.

_Gyan_ 6y ago
> Pfizer has the highest efficacy endpoint (95% at preventing infection Cite, please. Pfizer's primary outcome measure was symptomatic infection. Only Oxford/AZ in the UK carried out weekly PCR tests to check for asymptomatic infections.
- heyoni 6y ago
  Looks like it was edited? Yea, only symptomatic infections were tested by Pfizer iirc
- kenhwang 6y ago
  Reading the journal paper from AstraZeneca[1]. I don't think AZ can claim anything about preventing asymptomatic infections. You're right in that they're the only ones with that data, but that data is practically identical between control (37/2760) and vaccinated (34/2751) groups. Side note, the more I read about the AZ trials in detail, the more it becomes obvious how messy their trial was compared to the Pfizer/Moderna ones. They have so many more methodologies and outcomes and much smaller samples. [1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
  - _Gyan_ 6y ago
    They did find fewer asymptomatic infections in the half+full dose arm but the N is not large enough.

_Gyan_ 6y ago

> Pfizer has the highest efficacy endpoint (95% at preventing infection Cite, please. Pfizer's primary outcome measure was symptomatic infection. Only Oxford/AZ in the UK carried out weekly PCR tests to check for asymptomatic infections.

heyoni 6y ago
Looks like it was edited? Yea, only symptomatic infections were tested by Pfizer iirc
kenhwang 6y ago
Reading the journal paper from AstraZeneca[1]. I don't think AZ can claim anything about preventing asymptomatic infections. You're right in that they're the only ones with that data, but that data is practically identical between control (37/2760) and vaccinated (34/2751) groups. Side note, the more I read about the AZ trials in detail, the more it becomes obvious how messy their trial was compared to the Pfizer/Moderna ones. They have so many more methodologies and outcomes and much smaller samples. [1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
- _Gyan_ 6y ago
  They did find fewer asymptomatic infections in the half+full dose arm but the N is not large enough.